Co-ordinated malaria research for better policy and practice: the role of res...ACT Consortium
Prof. David Schellenberg from the London School of Hygiene & Tropical Medicine presents on behalf of the ACT Consortium at the European Congress on Tropical Medicine and International Health in Basel, Switzerland, 8 September 2015
Evaluating Impact: Lessons Learned from MEASURE EvaluationMEASURE Evaluation
During a September presentation at South Africa’s Department of Planning, Monitoring and Evaluation, Dr. Jason Smith shared experiences and lessons learned on evaluating impact from MEASURE Evaluation Phase III implementation
Co-ordinated malaria research for better policy and practice: the role of res...ACT Consortium
Prof. David Schellenberg from the London School of Hygiene & Tropical Medicine presents on behalf of the ACT Consortium at the European Congress on Tropical Medicine and International Health in Basel, Switzerland, 8 September 2015
Evaluating Impact: Lessons Learned from MEASURE EvaluationMEASURE Evaluation
During a September presentation at South Africa’s Department of Planning, Monitoring and Evaluation, Dr. Jason Smith shared experiences and lessons learned on evaluating impact from MEASURE Evaluation Phase III implementation
This presentation was given by Miriam Taegtmeyer at a meeting of the Overseas Development Institute on the 20 January 2016. In it she discusses the REACHOUT quality improvement approach.
HCV HUB planning and implementation website introduction with a specific focus on the benefits provided to scientific societies. http://hcvhub.deusto.es
HCV HUB planning and implementation website introduction with a specific focus on the benefits provided to health care professionals. http://hcvhub.deusto.es
HCV HUB planning and implementation website introduction with a specific focus on the benefits provided to patient associations. http://hcvhub.deusto.es
Keeping It Real:Resources for Implementing Evidence-based Public Health Progr...MargaretFarrell
Through this workshop, participants will
not only become familiar with how to use the tools they need to identity and address health outcomes, but
understand the benefits of virtual communities of practice as a means to engage researchers and practitioners around implementing cancer control programs.
will introduce participants to the Cancer Control P.L.A.N.E.T portal and the Research to Reality Community of Practice. (#NCIR2R)
Presentation given at the NATIONAL HEALTH OUTREACH CONFERENCE (#NHOC) Promoting Connections to Create Healthy Individuals, Families and Communities May 8, 2015
Presentation given at the USAID SQALE Symposium, Bridging the Quality Gap - Strengthening Quality Improvement in Community Health Services, by Charles Mito on behalf of MEASURE Evaluation PIMA. http://usaidsqale.reachoutconsortium.org/
How Community Engagement Fits Into The Mission Of The National Center for Adv...SC CTSI at USC and CHLA
Christopher Austin, MD, Director of the National Center for Advancing Translational Sciences (NCATS) shared his thoughts on how community engagement fits into the mission of NCATS at the recent CTSA Community Engagement Key Function Committee (KFC) conference. He proposed a revision of NCATS' mission: "To catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of interventions that tangibly improve human health across a wide range of human diseases and conditions." Learn more about NCATS http://www.ncats.nih.gov/
This presentation was given by Miriam Taegtmeyer at a meeting of the Overseas Development Institute on the 20 January 2016. In it she discusses the REACHOUT quality improvement approach.
HCV HUB planning and implementation website introduction with a specific focus on the benefits provided to scientific societies. http://hcvhub.deusto.es
HCV HUB planning and implementation website introduction with a specific focus on the benefits provided to health care professionals. http://hcvhub.deusto.es
HCV HUB planning and implementation website introduction with a specific focus on the benefits provided to patient associations. http://hcvhub.deusto.es
Keeping It Real:Resources for Implementing Evidence-based Public Health Progr...MargaretFarrell
Through this workshop, participants will
not only become familiar with how to use the tools they need to identity and address health outcomes, but
understand the benefits of virtual communities of practice as a means to engage researchers and practitioners around implementing cancer control programs.
will introduce participants to the Cancer Control P.L.A.N.E.T portal and the Research to Reality Community of Practice. (#NCIR2R)
Presentation given at the NATIONAL HEALTH OUTREACH CONFERENCE (#NHOC) Promoting Connections to Create Healthy Individuals, Families and Communities May 8, 2015
Presentation given at the USAID SQALE Symposium, Bridging the Quality Gap - Strengthening Quality Improvement in Community Health Services, by Charles Mito on behalf of MEASURE Evaluation PIMA. http://usaidsqale.reachoutconsortium.org/
How Community Engagement Fits Into The Mission Of The National Center for Adv...SC CTSI at USC and CHLA
Christopher Austin, MD, Director of the National Center for Advancing Translational Sciences (NCATS) shared his thoughts on how community engagement fits into the mission of NCATS at the recent CTSA Community Engagement Key Function Committee (KFC) conference. He proposed a revision of NCATS' mission: "To catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of interventions that tangibly improve human health across a wide range of human diseases and conditions." Learn more about NCATS http://www.ncats.nih.gov/
PIHCI programmatic grants webinar (en) for circulationAlexandra Enns
These are the slides from CIHR’s webinar providing information for the upcoming PIHCI Network Programmatic Grant funding opportunity.
The complete instructions are on ResearchNet: https://www.researchnet-recherchenet.ca/rnr16/vwOpprtntyDtls.do?prog=2734&view=currentOpps&org=CIHR&type=EXACT&resultCount=25&sort=program&next=1&all=1&masterList=true
The intersection of opioid use and HIV is well documented. More than one-third of all AIDS cases in the U.S. are directly or indirectly linked to injection drug use. Additionally, dependence and abuse of pain relievers is on the rise; people living with HIV/AIDS who suffer from chronic pain may be at particular risk. Opioids are highly addictive and mortality among illicit opioid users is estimated at 13 times that of the general population. The SPNS Buprenorphine Initiative investigated the effectiveness of integrating buprenorphine opioid abuse treatment into HIV primary care settings.
This Webcast is the first in a series under the new SPNS Integrating HIV Innovative Practices project (www.careacttarget.org/ihip) to assist providers in replicating SPNS work in their sites. This Webcast will introduce providers to the SPNS Buprenorphine Initiative, its findings, its synergy with the National HIV/AIDS Strategy, and provide an overview of opioid use and HIV.
The subsequent Webcast in the series will examine the clinical aspects of buprenorphine therapy, best practices, and implementation guidance. See also Integrating Buprenorphine Therapy Into HIV Primary Care Settings, a monograph on best practices, available at: https://careacttarget.org/content/integrating-buprenorphine-therapy-hiv-primary-care-settings.
Keynote address by Dr. Eric Goosby of UCSF, presented at CFAR HIV Research in International Settings (CHRIS) meeting in San Diego, October 1, 2014. Dr. Goosby discussed. "Global Health Delivery and Diplomacy: The Long Road to Sustainable Programs."
New Models of Care Strategy for Vanguards and PioneersHIMSS UK
Helen Arthur, Technology Vanguards Lead, NHS England
Mark Gollege, Local Government Association
Indi Singh, Interoperability Lead, NHS England
Andy Evans, Sherwood Forest Hospitals
Day 1: Challenges and opportunities for better detection, diagnosis and clini...KTN
The focus of this session is to explore how the UK health system is currently responding to the increasing number of patients with multiple long-term conditions and the impacts of healthcare inequalities on patient outcomes. We will also explore opportunities for businesses to bring about much needed innovations in the prevention, early diagnosis and management of multi-morbidity.
The mission of the Sexually Transmitted Diseases (STD) Control Program is to reduce the occurrence of STDs through disease surveillance, case and outbreak investigation, screening, preventive therapy, outreach, diagnosis, case management, and education.
Similar to Research to Guide Practice: Enhancing HIV/AIDs Platforms to Address NCDs in Low Resource Settings KUPFER & VORKOPER (20)
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Welcome to Secret Tantric, London’s finest VIP Massage agency. Since we first opened our doors, we have provided the ultimate erotic massage experience to innumerable clients, each one searching for the very best sensual massage in London. We come by this reputation honestly with a dynamic team of the city’s most beautiful masseuses.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
R3 Stem Cells and Kidney Repair A New Horizon in Nephrology.pptxR3 Stem Cell
R3 Stem Cells and Kidney Repair: A New Horizon in Nephrology" explores groundbreaking advancements in the use of R3 stem cells for kidney disease treatment. This insightful piece delves into the potential of these cells to regenerate damaged kidney tissue, offering new hope for patients and reshaping the future of nephrology.
2. HIV & NCDs
Early 1980s: HIV was a death sentence world wide
Late 1980s: ARTs changed all that – for developed
countries
2002-3 PEPFAR and Global Fund invest in building
health infrastructure in LMICs to deliver
treatment for HIV/AIDS
Currently: HIV is a chronic disease that people live with.
PLHIV die of co-morbid diseases such as
diabetes and cancer.
3. Enhancing PEPFAR
Platforms
• Leverage what’s there to address patient management
and prevention of NCDs for PLHIV
• Utilize existing human capital, health infrastructure, and data
systems developed to confront the HIV/AIDS crisis
• Lessons Learned:
• Monitoring and record keeping
• Affordable drugs and a reliable drug delivery system
• Community outreach and community testing
• Task shifting- development and training of a cadre of
community health workers
• link between research, policy and care delivery
4. Research to Guide Practice:
Enhancing HIV/AIDS Platforms to
Address NCDs in Low Resource Settings
5. Goal of the Project
To bring together researchers, implementers, and government
representatives to articulate practical goals, approaches, and
related research agenda to incorporate prevention, care and
treatment for NCDs into HIV/AIDS platforms in LMICs.
7. • Priority NCDs among people
living with HIV
▫ Cervical Cancer
▫ CVD/Stroke
▫ Depression
▫ Diabetes
Areas of Focus
8. First Steps
Sept, 2014 - July, 2015
Landscape analysis for each TOG
◦ Literature search and analysis
◦ Identification of priority research questions
Key informant interviews with MOH and academics in four countries
Review of countries’ NCD and HIV policies
Contributed to IeDEA network survey on health sites’ NCDs capacity
Technical Operating Groups (TOG)
Health Systems
Integration
Disease/Condition
Questions
Awareness, Education, and
Dissemination
9. Priority Research Questions
• What are the most effective/ cost-effective AED interventions
(e.g., peer and expert training models, CHW programs, and e-
health and m-health)?
• How can AED best be incorporated into and provide support for
existing prevention, care, and treatment interventions?
• What factors allow for successful implementation and scale-up of
evidence-based small-scale interventions?
Priority Research Questions
• What is the prevalence of NCDs and their risk factors in HIV
populations in SSA?
• How can we evaluate and improve the screening and
treatment of NCDs among PLHIV in resource-poor countries?
• How can we evaluate the potential for population-level scale
up of NCD prevention, screening, care, and treatment
programs?
Priority Research Questions
• What is needed for successful integration?
• What are the optimal program models to link PLHIV to
care/management and retention of those patients in HIV
programs?
• What kind of systemic interventions might be used to promote
readiness and capacity for integration of NCD diagnosis and
treatment strategies into current health care structures?
Landscape Outcomes:
Priority Research Questions
Health Systems
Integration
Disease/Condition
Questions
Awareness, Education,
and Dissemination
10. Landscape Analysis to Action
2nd Annual Meeting July 29-30, 2015
Objectives:
• Identify key research questions regarding the integration
of NCD services into HIV programs
• Develop an actionable strategy to address these questions
• Leverage the skills and influence of the people and
organizations at this meeting
11. 1. Incorporate NCD-PLHIV questions into existing surveys (e.g.,
IeDEA, WHO STEPS) and model NCD prevalence in PLHIV in
nine project focus countries.
2. Develop country-level compendium of existing NCD protocols
policies and guidelines for PLHIV with three countries.
3. Refine and prioritize HIV-NCD integration implementation
science research questions in collaboration with researchers
and funders in HIC and LMIC.
12. 4. Compare current HIV-NCD integration models by creating a
harmonized set of indicators, a framework, and an evaluation
paradigm for integration.
5. Prioritize and develop NCD awareness resources for PLHIV by
conducting a needs assessment with three focus countries and
develop resources for a country specific toolbox.
6. Edit and publish landscape analyses that project members
have collaboratively developed.
13. Thanks to our Steering Committee!
Atalay Alem, Addis Ababa University in Ethiopia
Wafaa El-Sadr, Columbia University
Eric Goosby, University of California, San Francisco
Naomi Levitt, University of Cape Town in South Africa
Beatrice Matanje-Mwagomba, Ministry of Health, Malawi
Miriam Rabkin, Columbia University
Doreen Ramogola Masire, University of Botswana
William Tierney, Dell Medical School in Austin, Texas
Gerald Yonga, Aga Khan University in Kenya
14. Thanks to Our Partners!
NIH
NCI, NHLBI, NIAID, NICHD, NIDDK, NIMH, NIMHD, NINDS, OAR
USG Agencies
CDC, DOD, OGAC, Peace Corps, USAID
Implementers
AMPATH, FHI-360, IeDEA, Jhpiego, Malawi, MOH, MSH, PATH, PIH
Additional Experts
CUNY, Global Fund, UNAIDS, University of Chicago, University of Washington